QIAGEN N.V. (QGEN) has partnered with South Korea-based GENCURIX, Inc. to develop oncology assays for the QIAcuityDx digital PCR platform. This collaboration marks GENCURIX as the first development partner in QIAGEN’s QIAcuityDx Partnering Program, enhancing digital PCR diagnostic accessibility. The initiative is expected to significantly advance QIAGEN’s Precision Diagnostics business.
The QIAcuityDx platform has seen over 2,700 placements since its launch, with plans to introduce more than 130 new assays for research applications by 2024. GENCURIX will leverage its expertise in IVD assay development to create multiple oncology tests and will be responsible for obtaining necessary regulatory approvals. Once approved, these assays will be marketed globally through QIAGEN’s established infrastructure.
QIAGEN’s market capitalization stands at $10.35 billion, with current stock performance remaining flat post-announcement. The global IVD market, valued at $108.30 billion in 2024, is projected to grow at an annual rate of 5.6% through 2030, driven by increasing demand for rapid and personalized diagnostics.
